Skip to main content
. Author manuscript; available in PMC: 2014 Jan 24.
Published in final edited form as: Cancer Chemother Pharmacol. 2009 Feb 17;64(4):803–810. doi: 10.1007/s00280-009-0931-y

Figure 1.

Figure 1

Companion Western blot analysis for the protein kinase c isoform η from PBMCs isolated from two patients (lanes 1–6; & 7–12) receiving (combination cisplatin (50 mg/m2) and Byro (50 mcg/m2 × 1hr). For both patients, a substantial depletion of the baseline signal (lanes 1, 2 and 7, 8) can be observed 28.3 and 48% respectively for the pkc isoform eta after the end of the Byro infusion (lanes 3,4 compared to 1,2 and lanes 9,10 compared to 7,8). This effect increased to respectively to 95.4 and 90% at 3 hours post Byro infusion (lanes 5,6 and 11,12).